Expression of T cell activation markers and cytokines produced by CAR-T cells were detected by flow cytometry.ResultsThe four CAR-T cell lines could effectively eliminate malignant NKTCL cells. They could be activated and produce inflammatory cytokines in a target-dependent manner. In vivo tests ...
MHC-I multimer staining, andbsingle-cell RNA sequencing (scRNA-seq) following antigen-reactive T-cell enrichment (ARTE). In the acute phase, SARS-CoV-2-specific CD8+T cells express activation markers (CD38 and HLA-DR
The uses of CD38 as a marker of cell activation and CD4 counts for monitoring of anti-retroviral therapy have been described by many investigations. Subsets of activated CD4+, CD8+ T lymphocyte defined by the effectiveness of membrane expression of the activating antigens CD38 and HLA-DR were ...
CD38 is commonly regarded as an activation marker for human T cells. Herein, we show that CD38 expression identifies a hypo-proliferative CD4+ T-cell subset that, following TCR stimulation, retains expression of naive cell surface markers including CD45RA, CD62L and CCR7. Hypo-proliferation was...
Surface Staining for T Cell Activation and Trafficking Markers Our previous work quantified CD38brightCD8+ TEM cells. Based on our previous work, we knew that CD38brightCD8+ T cells in both the acute GVHD and no GVHD cohorts lacked CD45RA and CCR7 expression. Because we had limited cryopreserv...
T-cell activation markers, CD38 and HLA-DR, were simultaneously monitored. The effects of in vitro TCR (T cell receptor) stimulation on proliferation, ... S Xing,J Fu,Z Zhang,... - 《Jaids》 被引量: 85发表: 2010年 Impaired CD4 T Cell Memory Response to Streptococcus pneumoniae Precedes...
We find a complex picture in which these markers alone, together and in combination with other markers that reflect T cell activation (CD38) help predict the speed of clinical progression and immune decline, with differing effects dependent on the duration of infection. We propose that therapies ...
No standard chemotherapy regimens have been defined yet for extranodal natural killer/T cell lymphoma (ENKTL), and the prognosis of patients with advanced or relapsed disease is very poor. Daratumumab, an investigated anti-cancer drug targeting CD38, has been of great interest in the treatment of...
We also investigated how this particular profile is generated.Compared to CD38+/HLA-DR+ cells, CD38-/HLA-DR+ cells exhibited lower expression of several activation markers, better survival capacity (Bcl-2 MFI, 367 [134-462] vs 638 [307-747], P = 0.001), higher frequency of ...
Immune activation markers and CD4+ T-cell counts in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr (1992) 5:1273-4. doi:10.1097/... R Zangerle,H Wachter,D Fuchs - 《Journal of Acquired Immune Deficiency Syndromes》 ...